DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR MITOXANTRONE HYDROCHLORIDE
Clinical Trials for Mitoxantrone Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00002003 | Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas | Completed | Lederle Laboratories | Phase 2 | To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas. |
| NCT00002259 | Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma | Completed | Lederle Laboratories | Phase 2 | To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma. |
| NCT00002474 | Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer | Completed | Loyola University | Phase 2 | RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, carboplatin, and mitoxantrone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with autologous bone marrow transplant may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: This phase II trial is studying how well chemotherapy and autologous bone marrow transplant work in treating patients with refractory or recurrent ovarian cancer. |
| NCT00002498 | Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer | Unknown status | Leiden University Medical Center | Phase 2 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different combinations may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of cyclophosphamide, methotrexate, and fluorouracil with mitoxantrone in treating older patients with recurrent or metastatic breast cancer. |
| NCT00002514 | Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission | Completed | Medical Research Council | Phase 3 | RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Mitoxantrone Hydrochloride
Condition Name
Condition MeSH
Clinical Trial Locations for Mitoxantrone Hydrochloride
Trials by Country
Clinical Trial Progress for Mitoxantrone Hydrochloride
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Mitoxantrone Hydrochloride
Sponsor Name
| Sponsor Name for Mitoxantrone Hydrochloride | |
| Sponsor | Trials |
| National Cancer Institute (NCI) | 69 |
| Fred Hutchinson Cancer Research Center | 9 |
| European Organisation for Research and Treatment of Cancer - EORTC | 8 |
| [disabled in preview] | 16 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Export unavailable in trial.
Subscribe for complete access.
